Compare NBTB & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBTB | HAE |
|---|---|---|
| Founded | 1856 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 1995 | 1996 |
| Metric | NBTB | HAE |
|---|---|---|
| Price | $45.43 | $60.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $52.00 | ★ $84.13 |
| AVG Volume (30 Days) | 200.9K | ★ 546.0K |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | 12.12 | ★ 44.54 |
| EPS | ★ 3.33 | 2.46 |
| Revenue | $182,952,000.00 | ★ $910,373,000.00 |
| Revenue This Year | $16.82 | N/A |
| Revenue Next Year | $4.88 | $5.23 |
| P/E Ratio | ★ $13.56 | $24.55 |
| Revenue Growth | ★ 10.40 | N/A |
| 52 Week Low | $39.14 | $47.32 |
| 52 Week High | $46.92 | $87.32 |
| Indicator | NBTB | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 66.77 | 54.18 |
| Support Level | $41.68 | $48.47 |
| Resistance Level | $45.97 | $66.86 |
| Average True Range (ATR) | 0.81 | 1.82 |
| MACD | 0.41 | 0.58 |
| Stochastic Oscillator | 86.65 | 83.20 |
NBT Bancorp Inc is a financial holding company that operates through its subsidiaries. The company's principal sources of revenue include management fees and dividends it receives through its subsidiaries. Its business, predominantly conducted through NBT Bank, consists of providing commercial banking, retail banking, and wealth management services to customers in its market area, which includes upstate New York, northeastern Pennsylvania, southern New Hampshire, western Massachusetts, Vermont, southern Maine, and central and northwestern Connecticut. The company's reportable segments are Banking and Retirement Plan Administration. A majority of its revenue is generated from the Banking segment.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.